Dr. Doroshow is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3a44 Bidg 31
31 Center Drive
Bethesda, MD 20892Phone+1 301-496-4291- Is this information wrong?
Education & Training
Massachusetts General HospitalResidency, Internal Medicine, 1973 - 1975
Harvard Medical SchoolClass of 1973
Certifications & Licensure
MA State Medical License 1974 - 2025
CA State Medical License 1975 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function Start of enrollment: 1996 Dec 01
- Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer Start of enrollment: 1996 Jun 01
- S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach Start of enrollment: 2001 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- Association of changes in expression ofandgenes after drug treatment with cancer cell line sensitivity to kinase inhibitors.Julia Krushkal, Yingdong Zhao, Kyle Roney, Weimin Zhu, Alan Brooks, Deborah Wilsker, Ralph E Parchment, Lisa M McShane, James H Doroshow> ;Epigenetics. 2024 Dec 1
- 2 citationsIntegration of Computational Docking into Anti-Cancer Drug Response Prediction Models.Narykov, O., Zhu, Y., Brettin, T., Evrard, Y., Partin, A., Shukla, M., Xia, F., Clyde, A., Vasanthakumari, P., Stevens, R., Doroshow, J.> ;Cancers. 2023 Dec 21
- Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors.Arjun Mittra, Geraldine H O' Sullivan Coyne, Jennifer Zlott, Shivaani Kummar, Robert Meehan, Lawrence Rubinstein, Lamin Juwara, Deborah Wilsker, Jiuping Ji, Brandon Mi...> ;Cancer Chemotherapy and Pharmacology. 2024 Mar 1
- Join now to see all
Press Mentions
Pragmatica-Lung Trial Begins Enrolling Patients with NSCLC Who Did Not Respond to Previous TherapyApril 14th, 2023- Pragmatica-Lung Study, a Streamlined Model for Future Cancer Clinical Trials, Begins Enrolling PatientsApril 12th, 2023
- Research Shows the Benefits of Screening AML Patients in Remission for Residual Disease Before Bone Marrow TransplantMarch 7th, 2023
- Join now to see all
Grant Support
- Roles Of Nadph Oxidase 5 And Dual Oxidase 2 In CancerNational Cancer Institute2010–2011
- Phase 01 Clinical TrialsNational Cancer Institute2010–2011
- Nadph Oxidase 1: A Novel Target For Colon Cancer TherapyNational Cancer Institute2010–2011
- Roles Of Nadph Oxidase 5 And Dual Oxidase 2 In CancerDivision Of Basic Sciences - Nci2009
- Phase 01 Clinical TrialsDivision Of Basic Sciences - Nci2009
- Nadph Oxidase 1: A Novel Target For Colon Cancer TherapyDivision Of Basic Sciences - Nci2009
- Phase 01 Clinical TrialsNational Cancer Institute2008
- Nadph Oxidase 1: A Novel Target For Colon Cancer TherapyNational Cancer Institute2007–2008
- Nadph Oxidase 1: A Novel Target For Colon Cancer TherapyDivision Of Basic Sciences - Nci2005–2006
- Phi-39: Phase I Trial Of #7389 (Halichondrin B Analog)National Center For Research Resources2004
- A Phase I Pharmacokinetic Study Of STI-571 In PatientsNational Center For Research Resources2004
- CITY Of HOPE Southwest Group Clinical TrialsNational Cancer Institute1999–2004
- Oncology Research Career Development ProgramNational Cancer Institute2003
- Phase I Molecular And Clinical Pharmacodynamic TrialsNational Cancer Institute1999–2003
- MDR1 Gene Therapy In CD34+ Cells And SCID MiceNational Cancer Institute2002
- Clinical Oncology Research Career Development ProgramNational Cancer Institute1999–2002
- Pharmacodynamic Phase II Breast, Lung And Ovary TrialsNational Cancer Institute1997–2001
- National Cancer Institute Initial Review GroupNational Cancer Institute1999–2000
- Phase I Molecular And Clinical Pharmacodynamic TrialsNational Cancer Institute1998
- CITY Of HOPE Southwest Group Clinical TrialsNational Cancer Institute1998
- Clinical Oncology Research Career Development ProgramNational Cancer Institute1997–1998
- Molecular Breast Cancer Therapy And CarcinogenesisNational Cancer Institute1994–1997
- Southwest Oncology Group--Clinical TrialsNational Cancer Institute1993–1997
- Pharmacodynamic Phase II Breast, Lung And Ovary TrialsNational Cancer Institute1994–1996
- Clinical OncologyNational Cancer Institute1994–1996
- Molecular Breast Cancer Therapy And CarcinogenesisNational Cancer Institute1994
- Coh Clinical Oncology Research Development ProgramNational Cancer Institute1992–1993
- Coh Southwest Oncology Group Clinical TrialsNational Cancer Institute1988–1992
- Cancer Center Support GrantNational Cancer Institute1987–1990
- Oxygen Radicals And Anticancer QuinonesNational Cancer Institute1985–1986
Professional Memberships
- Member
Hospital Affiliations
NIH Clinical CenterBethesda, Maryland
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
